0001213900-23-097753.txt : 20231221 0001213900-23-097753.hdr.sgml : 20231221 20231221172153 ACCESSION NUMBER: 0001213900-23-097753 CONFORMED SUBMISSION TYPE: 10-K/A PUBLIC DOCUMENT COUNT: 18 CONFORMED PERIOD OF REPORT: 20230630 FILED AS OF DATE: 20231221 DATE AS OF CHANGE: 20231221 FILER: COMPANY DATA: COMPANY CONFORMED NAME: InMed Pharmaceuticals Inc. CENTRAL INDEX KEY: 0001728328 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 10-K/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-39685 FILM NUMBER: 231506218 BUSINESS ADDRESS: STREET 1: SUITE 310, 815 W. HASTINGS STREET CITY: VANCOUVER STATE: A1 ZIP: V6C 1B4 BUSINESS PHONE: (604) 669-7207 MAIL ADDRESS: STREET 1: SUITE 310, 815 W. HASTINGS STREET CITY: VANCOUVER STATE: A1 ZIP: V6C 1B4 10-K/A 1 f10k2023a1_inmedphar.htm AMENDMENT NO. 1 TO FORM 10-K

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 10-K/A

(Amendment No. 1)

 

(Mark One)

 ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the fiscal year ended June 30, 2023

 

OR

 

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from          to          

 

Commission file number: 001-39685

 

INMED PHARMACEUTICALS INC.

(Exact name of registrant as specified in its charter)

 

British Columbia, Canada   98-1428279
(State or other jurisdiction of
incorporation or organization)		   (IRS employer
Identification number)
     
Suite 310 – 815 W Hastings, Vancouver, B.C.,
Canada		   V6C 1B4
(Address of principal executive office)   (Zip Code)

 

(604) 669-7207

(Registrant’s telephone number, including area code)

 

Securities registered pursuant to Section 12(b) of the Exchange Act:

 

Title of Each Class   Trading Symbol   Name of Each Exchange On
Which Registered
Common Stock, no par value   INM   The Nasdaq Capital Market

 

Securities registered pursuant to Section 12(g) of the Act: None

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act. Yes ☐ No ☒

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically, every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐   Accelerated filer ☐
Non-accelerated filer ☒   Smaller reporting company ☒
      Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant has fi led a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting fi rm that prepared or issued its audit report. ☐

 

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐

 

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

 

As of December 31, 2022, the last business day of the Registrant’s most recently completed second fiscal quarter, the aggregate market value of the Company’s voting and non-voting common equity held by non-affiliates of the Registrant was $3,180,248.

 

On September 29, 2023, there were 3,328,191 shares of the registrant’s common stock outstanding.

 

DOCUMENTS INCORPORATED BY REFERENCE

 

None.

 

Auditor Name:   Auditor Location:   Auditor Firm ID:
Marcum LLP   New York, NY   688

 

 

 

 

 

 

 

EXPLANATORY NOTE

 

We are filing this Amendment No. 1 to our Annual Report on Form 10-K solely for the purpose of updating our auditor’s consent in Exhibit 23.1 to include our Registration Statement on Form S-8 (File No. 333-268356).

 

Outside of the change to the exhibit noted above and the updated certifications of the Chief Executive Officer and Chief Financial Officer, this Form 10-K/A does not otherwise amend, supplement, update or revise any portion of the original Form 10-K which remains unchanged since the date of its filing. Furthermore, this Form 10-K/A does not change any previously reported financial results, nor does it reflect events occurring after the date of the original Form 10-K. Information not affected by this Form 10-K/A remains unchanged and reflects the disclosures made at the time the original Form 10-K was filed.

 

i

 

 

PART IV

 

ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES

 

The following documents are being filed as part of this report:

 

  (1)

Financial Statements

 

The financial statements required by this item were submitted with the Original Form 10-K. Refer to Part II, Item 8, “Financial Statements and Supplementary Data” of the Original Form 10-K.

  

  (2) Financial statement schedules have been omitted because of the absence of conditions under which they are required or because the required information is included in the financial statements or notes thereto submitted as part of the Original Form 10-K.

 

  (3) A list of exhibits filed with this report is found below.

 

EXHIBIT    
NUMBER   DESCRIPTION
     
23.1   Consent of Marcum LLP.
31.1   Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2   Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1   Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2   Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS*   Inline XBRL Instance Document.
101.SCH*   Inline XBRL Taxonomy Extension Schema Document.
101.CAL*   Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF*   Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB*   Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE*   Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104*   Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

 

*Previously filed.

 

ITEM 16. 10-K SUMMARY

 

Not applicable.

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  INMED PHARMACEUTICALS INC.
  (Registrant)
     
December 21, 2023 By: /s/ Jonathan Tegge
    Jonathan Tegge
    Interim Chief Financial Officer
and Principal Accounting Officer

 

Pursuant to the requirements of the Securities and Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

 

Signature   Title   Date
         
/s/ Eric A. Adams   President, Chief Executive Officer and Director   December 21, 2023
Eric A. Adams   (Principal Executive Officer)    
         
/s/ Jonathan Tegge   Interim Chief Financial Officer   December 21, 2023
Jonathan Tegge   (Principal Financial Officer and Principal Accounting Officer)    
         
/s/ Andrew Hull   Director (Chairman to the Board of Directors)   December 21, 2023
Andrew Hull        
         
/s/ Janet Grove   Director   December 21, 2023
Janet Grove        
         
/s/ Bryan Baldasare   Director   December 21, 2023
Bryan Baldasare        
         
/s/ Nicole Lemerond   Director   December 21, 2023
Nicole Lemerond        

 

 

2

 

 

 

 

true FY 0001728328 0001728328 2022-07-01 2023-06-30 0001728328 2022-12-31 0001728328 2023-09-29 iso4217:USD xbrli:shares
EX-23.1 2 f10k2023a1ex23-1_inmedphar.htm CONSENT OF MARCUM LLP

Exhibit 23.1

 

Independent Registered Public Accounting Firm’s Consent

 

We consent to the incorporation by reference in this Registration Statement of InMed Pharmaceuticals Inc. on Forms S-1 [File Nos. 333-253925, 333-257858, 333-265731, 333-267831 and 333-268700], on Forms S-3 [File Nos. 333-262533 and 333-264187], and on Forms S-8 [File Nos. 333-253912, 333-260323, and 333-268356] of our report dated September 29, 2023, which includes an explanatory paragraph as to the Company’s ability to continue as a going concern with respect to our audit of the consolidated financial statements of InMed Pharmaceuticals Inc. as of June 30, 2023 and for the year then ended, appearing in the Annual Report on Form 10-K of InMed Pharmaceuticals Inc. for the year ended June 30, 2023.

 

/s/ Marcum llp

 

Marcum llp

New York, NY

December 21, 2023

 

 EX-31.1 3 f10k2023a1ex31-1_inmedphar.htm CERTIFICATION

Exhibit 31.1

 

Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 

I, Eric A. Adams, certify that:

 

1. I have reviewed this Amendment No. 1 to the Annual Report on Form 10-K/A of InMed Pharmaceuticals Inc.;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a- 15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s fourth fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: December 21, 2023

 

/s/ Eric A. Adams  
Name:  Eric A. Adams  
Title: President and Chief Executive Officer  

  

 EX-31.2 4 f10k2023a1ex31-2_inmedphar.htm CERTIFICATION

Exhibit 31.2

 

Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 

I, Jonathan Tegge, certify that:

 

1. I have reviewed this Amendment No. 1 to the Annual Report on Form 10-K/A of InMed Pharmaceuticals Inc.;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a- 15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s fourth fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: December 21, 2023

 

/s/ Jonathan Tegge  
Name:  Jonathan Tegge  
Title: Interim Chief Financial Officer  

 

 

 

 EX-32.1 5 f10k2023a1ex32-1_inmedphar.htm CERTIFICATION

Exhibit 32.1

 

Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

 

Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, I, Eric A. Adams, the President and Chief Executive Officer of InMed Pharmaceuticals Inc. (the “Company”), hereby certify that, to my knowledge:

 

1.The Annual Report on Form 10-K/A for the year ended June 30, 2023 (the “Report”) of the Company fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934; and

 

2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: December 21, 2023

 

/s/ Eric A. Adams  
Name:  Eric A. Adams  
Title: President and Chief Executive Officer  

 

 

 

 EX-32.2 6 f10k2023a1ex32-2_inmedphar.htm CERTIFICATION

Exhibit 32.2

 

Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

 

Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, I, Jonathan Tegge, the Chief Financial Officer of InMed Pharmaceuticals Inc. (the “Company”), hereby certify that, to my knowledge:

 

1.The Annual Report on Form 10-K/A for the year ended June 30, 2023 (the “Report”) of the Company fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934; and

 

2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: December 21, 2023

 

/s/ Jonathan Tegge  
Name:  Jonathan Tegge  
Title: Interim Chief Financial Officer  

 

 

 

 EX-101.SCH 7 inm-20230630.xsd XBRL SCHEMA FILE 000 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink EX-101.DEF 8 inm-20230630_def.xml XBRL DEFINITION FILE EX-101.LAB 9 inm-20230630_lab.xml XBRL LABEL FILE EX-101.PRE 10 inm-20230630_pre.xml XBRL PRESENTATION FILE XML 11 R1.htm IDEA: XBRL DOCUMENT v3.23.4
Document And Entity Information - USD ($)
 12 Months Ended
Jun. 30, 2023
Sep. 29, 2023
Dec. 31, 2022
Document Information Line Items      
Entity Registrant Name INMED PHARMACEUTICALS INC.    
Trading Symbol INM    
Document Type 10-K/A    
Current Fiscal Year End Date --06-30    
Entity Common Stock, Shares Outstanding   3,328,191  
Entity Public Float     $ 3,180,248
Amendment Flag true    
Amendment Description We are filing this Amendment No. 1 to our Annual Report on Form 10-K solely for the purpose of updating our auditor’s consent in Exhibit 23.1 to include our Registration Statement on Form S-8 (File No. 333-268356).Outside of the change to the exhibit noted above and the updated certifications of the Chief Executive Officer and Chief Financial Officer, this Form 10-K/A does not otherwise amend, supplement, update or revise any portion of the original Form 10-K which remains unchanged since the date of its filing. Furthermore, this Form 10-K/A does not change any previously reported financial results, nor does it reflect events occurring after the date of the original Form 10-K. Information not affected by this Form 10-K/A remains unchanged and reflects the disclosures made at the time the original Form 10-K was filed.    
Entity Central Index Key 0001728328    
Entity Current Reporting Status Yes    
Entity Voluntary Filers No    
Entity Filer Category Non-accelerated Filer    
Entity Well-known Seasoned Issuer No    
Document Period End Date Jun. 30, 2023    
Document Fiscal Year Focus 2023    
Document Fiscal Period Focus FY    
Entity Small Business true    
Entity Emerging Growth Company true    
Entity Shell Company false    
Entity Ex Transition Period false    
ICFR Auditor Attestation Flag false    
Document Annual Report true    
Document Transition Report false    
Entity File Number 001-39685    
Entity Incorporation, State or Country Code A1    
Entity Tax Identification Number 98-1428279    
Entity Address, Address Line One Suite 310 – 815 W Hastings    
Entity Address, Address Line Two Vancouver    
Entity Address, City or Town B.C    
Entity Address, Country CA    
Entity Address, Postal Zip Code V6C 1B4    
City Area Code (604)    
Local Phone Number 669-7207    
Title of 12(b) Security Common Stock, no par value    
Security Exchange Name NASDAQ    
Entity Interactive Data Current Yes    
Document Financial Statement Error Correction [Flag] false    
Documents Incorporated by Reference [Text Block]

DOCUMENTS INCORPORATED BY REFERENCE

None.

    
Auditor Name Marcum LLP    
Auditor Location New York, NY    
Auditor Firm ID 688    
XML 12 f10k2023a1_inmedphar_htm.xml IDEA: XBRL DOCUMENT 0001728328 2022-07-01 2023-06-30 0001728328 2022-12-31 0001728328 2023-09-29 iso4217:USD shares 10-K/A true 2023-06-30 --06-30 2023 false 001-39685 INMED PHARMACEUTICALS INC. A1 98-1428279 Suite 310 – 815 W Hastings Vancouver B.C CA V6C 1B4 (604) 669-7207 Common Stock, no par value INM NASDAQ No No Yes Yes Non-accelerated Filer true true false false false false 3180248 3328191 <p style="font: 10pt Times New Roman,serif; margin: 0; text-align: center"><b>DOCUMENTS INCORPORATED BY REFERENCE</b></p><p style="font: 10pt Times New Roman,serif; margin: 0; text-align: justify; text-indent: 0.5in">None.</p> Marcum LLP New York, NY 688 We are filing this Amendment No. 1 to our Annual Report on Form 10-K solely for the purpose of updating our auditor’s consent in Exhibit 23.1 to include our Registration Statement on Form S-8 (File No. 333-268356).Outside of the change to the exhibit noted above and the updated certifications of the Chief Executive Officer and Chief Financial Officer, this Form 10-K/A does not otherwise amend, supplement, update or revise any portion of the original Form 10-K which remains unchanged since the date of its filing. Furthermore, this Form 10-K/A does not change any previously reported financial results, nor does it reflect events occurring after the date of the original Form 10-K. Information not affected by this Form 10-K/A remains unchanged and reflects the disclosures made at the time the original Form 10-K was filed. true FY 0001728328 EXCEL 13 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 14 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 15 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 16 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.4 html 3 41 1 false 0 0 false 2 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.inmedpharma.com/role/DocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports f10k2023a1_inmedphar.htm inm-20230630.xsd inm-20230630_def.xml inm-20230630_lab.xml inm-20230630_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 18 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "f10k2023a1_inmedphar.htm": { "nsprefix": "inm", "nsuri": "http://www.inmedpharma.com/20230630", "dts": { "inline": { "local": [ "f10k2023a1_inmedphar.htm" ] }, "schema": { "local": [ "inm-20230630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/sic/2023/sic-2023.xsd" ] }, "definitionLink": { "local": [ "inm-20230630_def.xml" ] }, "labelLink": { "local": [ "inm-20230630_lab.xml" ] }, "presentationLink": { "local": [ "inm-20230630_pre.xml" ] } }, "keyStandard": 41, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 3, "http://xbrl.sec.gov/dei/2023": 3 }, "contextCount": 3, "entityCount": 1, "segmentCount": 0, "elementCount": 44, "unitCount": 2, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 41 }, "report": { "R1": { "role": "http://www.inmedpharma.com/role/DocumentAndEntityInformation", "longName": "000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c0", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "f10k2023a1_inmedphar.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "f10k2023a1_inmedphar.htm", "first": true, "unique": true } } }, "tag": { "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://www.inmedpharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r1" ] }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorLocation", "presentation": [ "http://www.inmedpharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Auditor Location", "label": "Auditor Location" } } }, "auth_ref": [ "r4", "r5", "r6" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.inmedpharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorName", "presentation": [ "http://www.inmedpharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Auditor Name", "label": "Auditor Name" } } }, "auth_ref": [ "r4", "r5", "r6" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.inmedpharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://www.inmedpharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Annual Report", "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r4", "r5", "r6" ] }, "inm_DocumentAndEntityInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.inmedpharma.com/20230630", "localname": "DocumentAndEntityInformationAbstract", "auth_ref": [] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://www.inmedpharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r1" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.inmedpharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.inmedpharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorFirmId", "presentation": [ "http://www.inmedpharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Auditor Firm ID", "label": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": [ "r4", "r5", "r6" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://www.inmedpharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r1" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.inmedpharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.inmedpharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationLineItems", "presentation": [ "http://www.inmedpharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://www.inmedpharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Documents Incorporated by Reference [Text Block]", "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r2" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.inmedpharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r3" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://www.inmedpharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Public Float", "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.inmedpharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.inmedpharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://www.inmedpharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Country", "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.inmedpharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.inmedpharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.inmedpharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.inmedpharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.inmedpharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_IcfrAuditorAttestationFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "IcfrAuditorAttestationFlag", "presentation": [ "http://www.inmedpharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "ICFR Auditor Attestation Flag", "label": "ICFR Auditor Attestation Flag" } } }, "auth_ref": [ "r4", "r5", "r6" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.inmedpharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://www.inmedpharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Ex Transition Period", "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r11" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.inmedpharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://www.inmedpharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r7" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.inmedpharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.inmedpharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.inmedpharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://www.inmedpharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Well-known Seasoned Issuer", "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r10" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://www.inmedpharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Voluntary Filers", "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.inmedpharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.inmedpharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r9" ] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.inmedpharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line Two", "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_DocumentFinStmtErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFinStmtErrorCorrectionFlag", "presentation": [ "http://www.inmedpharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Financial Statement Error Correction [Flag]", "label": "Document Financial Statement Error Correction [Flag]", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth_ref": [ "r4", "r5", "r6", "r8" ] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://www.inmedpharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Description", "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.inmedpharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.inmedpharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationTable", "presentation": [ "http://www.inmedpharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 19 0001213900-23-097753-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-23-097753-xbrl.zip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